Athenex Inc (ATNX) Receives Consensus Rating of “Hold” from Analysts

Shares of Athenex Inc (NASDAQ:ATNX) have earned a consensus rating of “Hold” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $24.33.

Several research firms have commented on ATNX. ValuEngine raised shares of Athenex from a “hold” rating to a “buy” rating in a report on Friday, August 3rd. BidaskClub raised shares of Athenex from a “hold” rating to a “buy” rating in a report on Wednesday, June 20th. Finally, Zacks Investment Research lowered shares of Athenex from a “hold” rating to a “sell” rating in a report on Friday, August 17th.

NASDAQ:ATNX traded down $0.08 during mid-day trading on Friday, hitting $13.37. The company’s stock had a trading volume of 199,296 shares, compared to its average volume of 330,567. Athenex has a 1 year low of $13.22 and a 1 year high of $20.90. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -5.76 and a beta of -1.66.

Athenex (NASDAQ:ATNX) last posted its quarterly earnings results on Tuesday, August 14th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.10). Athenex had a negative net margin of 122.29% and a negative return on equity of 73.37%. The business had revenue of $11.57 million during the quarter. On average, research analysts predict that Athenex will post -2 EPS for the current year.

In other news, CEO Johnson Yiu Nam Lau bought 2,000 shares of the stock in a transaction dated Thursday, September 27th. The shares were acquired at an average cost of $15.66 per share, with a total value of $31,320.00. Following the purchase, the chief executive officer now directly owns 2,847,422 shares in the company, valued at approximately $44,590,628.52. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Jinn Wu bought 5,000 shares of the stock in a transaction dated Monday, August 20th. The shares were purchased at an average cost of $17.20 per share, for a total transaction of $86,000.00. Following the completion of the purchase, the director now owns 4,000 shares in the company, valued at $68,800. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 14,500 shares of company stock worth $236,745 and have sold 344,317 shares worth $5,859,972. Corporate insiders own 29.50% of the company’s stock.

Several hedge funds have recently bought and sold shares of ATNX. Schwab Charles Investment Management Inc. boosted its stake in shares of Athenex by 303.9% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 126,323 shares of the company’s stock worth $2,149,000 after acquiring an additional 95,048 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Athenex by 95.1% during the 1st quarter. Northern Trust Corp now owns 146,236 shares of the company’s stock worth $2,487,000 after acquiring an additional 71,287 shares in the last quarter. BlackRock Inc. lifted its stake in Athenex by 54.8% in the 1st quarter. BlackRock Inc. now owns 1,683,185 shares of the company’s stock valued at $28,631,000 after buying an additional 596,200 shares in the last quarter. Citigroup Inc. lifted its stake in Athenex by 879.5% in the 1st quarter. Citigroup Inc. now owns 26,270 shares of the company’s stock valued at $447,000 after buying an additional 23,588 shares in the last quarter. Finally, A.R.T. Advisors LLC purchased a new position in Athenex in the 1st quarter valued at about $289,000. 19.72% of the stock is currently owned by institutional investors and hedge funds.

Athenex Company Profile

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.

Recommended Story: Why is the ex-dividend date different from the record date?

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply